Your browser doesn't support javascript.
loading
Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers.
Lozano, Rebeca; Castro, Elena; Lopez-Campos, Fernando; Thorne, Heather; Ramirez-Backhaus, Miguel; Aragon, Isabel M; Cendón-Florez, Ylenia; Gutierrez-Pecharroman, Ana; Salles, Daniela C; Romero-Laorden, Nuria; Lorente, David; González-Peramato, Pilar; Calatrava, Ana; Alonso, Concepción; Anido, Urbano; Arévalo-Lobera, Sara; Balmaña, Judith; Chirivella, Isabel; Juan-Fita, María José; Llort, Gemma; Y Cajal, Teresa Ramón; Almagro, Elena; Alameda, Daniel; López-Casas, Pedro P; Herrera, Bernardo; Mateo, Joaquin; Pritchard, Colin C; Antonarakis, Emmanuel S; Lotan, Tamara L; Rubio-Briones, José; Sandhu, Shahneen; Olmos, David.
Affiliation
  • Lozano R; Genitourinary Cancer Translational Research Unit, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain; Department of Medical Oncology, Hospital Universitario de Salamanca, Salamanca, Spain.
  • Castro E; Genitourinary Cancer Translational Research Unit, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain; Translational Cancer Genetics Group, Hospital Universitario 12 de Octubre, Madrid, Spain. Electronic address: ecastro.imas12@h12o.es.
  • Lopez-Campos F; Department of Radiation Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Thorne H; kConFab, The Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Ramirez-Backhaus M; Urology Department, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
  • Aragon IM; Genitourinary Cancer Translational Research Unit, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain.
  • Cendón-Florez Y; Genitourinary Cancer Translational Research Unit, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain.
  • Gutierrez-Pecharroman A; Genitourinary Cancer Translational Research Unit, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain; Department of Pathology, Hospital de Getafe, Getafe, Spain.
  • Salles DC; Department of Pathology, John Hopkins University School of Medicine, Baltimore, USA.
  • Romero-Laorden N; Medical Oncology Department, Hospital Universitario La Princesa, Madrid, Spain.
  • Lorente D; Medical Oncology Department, Hospital Provincial de Castellón, Castellón de la Plana, Spain.
  • González-Peramato P; Pathology Department, Hospital Universitario La Paz, Universidad Autónoma de Madrid, Madrid, Spain.
  • Calatrava A; Pathology Department, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
  • Alonso C; Genetics Department, Hospital Universitario La Princesa, Madrid, Spain.
  • Anido U; Medical Oncology Department, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.
  • Arévalo-Lobera S; Medical Oncology Department, Hospital Universitario de Donostia, Donostia, Spain.
  • Balmaña J; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Vall d´HebronUniversity Hospital, Barcelona, Spain.
  • Chirivella I; Medical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.
  • Juan-Fita MJ; Medical Oncology Department, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
  • Llort G; Medical Oncology Department, Parc Taulí Hospital Universitari, Sabadell, Spain.
  • Y Cajal TR; Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Almagro E; Medical Oncology Department, Hospital Universitario Quirón, Pozuelo de Alarcón, Madrid, Spain.
  • Alameda D; Genitourinary Cancer Translational Research Unit, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain.
  • López-Casas PP; Genomics and Therapeutics in Prostate Cancer Group, Medical Oncology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria 12 de Octubre (Imas12), Madrid, Spain.
  • Herrera B; Genitourinary Cancer Translational Research Unit, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain; Urology Department, Hospital Universitario Virgen de la Victoria, Málaga, Spain.
  • Mateo J; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Vall d´HebronUniversity Hospital, Barcelona, Spain.
  • Pritchard CC; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, USA.
  • Antonarakis ES; Department of Medical Oncology, John Hopkins University School of Medicine, Baltimore, USA.
  • Lotan TL; Department of Pathology, John Hopkins University School of Medicine, Baltimore, USA.
  • Rubio-Briones J; Urology Department, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
  • Sandhu S; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
  • Olmos D; Genomics and Therapeutics in Prostate Cancer Group, Medical Oncology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria 12 de Octubre (Imas12), Madrid, Spain.
Eur J Cancer ; 185: 105-118, 2023 05.
Article in En | MEDLINE | ID: mdl-36972661
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / DNA Copy Number Variations Type of study: Prognostic_studies Limits: Humans / Male Language: En Journal: Eur J Cancer Year: 2023 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / DNA Copy Number Variations Type of study: Prognostic_studies Limits: Humans / Male Language: En Journal: Eur J Cancer Year: 2023 Document type: Article Affiliation country: Country of publication: